IBJNews

Ariad patent victory over Lilly among largest in 2006

Back to TopCommentsE-mailPrint
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.

A Massachusetts jury awarded Ariad $65.2 million after unanimously agreeing that Lilly’s Evista and Xigris drugs infringed on a patent held by the Cambridge, Mass., drug developer.
 
Jury awards for patent verdicts nearly tripled last year from 2005—to $1 billion—as companies took to the courts to protect valuable technology, and increasingly trusted juries to sort through complex disagreements.
 
The largest jury award last year for infringing a patent, $307 million, went to Los Altos, Calif.-based Rambus Inc. after it sued Hynix Semiconductor Inc. of Inchon, South Korea, over use of random access memory. A judge cut the figure to $133.4 million.
ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT